دورية أكاديمية
Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer.
| العنوان: | Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer. |
|---|---|
| المؤلفون: | Lin F; State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhang LP; Department of Oncology, Guangdong Province Hospital of Integrated of Traditional Chinese and Western Medicine, Foshan, China., Xie SY; State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China., Huang HY; State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China., Chen XY; State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China., Jiang TC; State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China., Guo L; State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China., Lin HX; State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China. |
| المصدر: | Frontiers in oncology [Front Oncol] 2022 Apr 13; Vol. 12, pp. 830138. Date of Electronic Publication: 2022 Apr 13 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Background: To build a predictive scoring model based on simple immune and inflammatory parameters to predict postoperative survival in patients with breast cancer. Methods: We used a brand-new immuno-inflammatory index-pan-immune-inflammation value (PIV)-to retrospectively evaluate the relationship between PIV and overall survival (OS), and based on the results of Cox regression analysis, we established a simple scoring prediction model based on several independent prognostic parameters. The predictive accuracy of the model was evaluated and independently validated. Results: A total of 1,312 patients were included for analysis. PIV was calculated as follows: neutrophil count (10 9 /L) × platelet count (10 9 /L) × monocyte count (10 9 /L)/lymphocyte count (10 9 /L). According to the best cutoff value of PIV, we divided the patients into two different subgroups, high PIV (PIV > 310.2) and low PIV (PIV ≤ 310.2), associated with significantly different survival outcomes (3-year OS, 80.26% vs. 86.29%, respectively; 5-year OS, 62.5% vs. 71.55%, respectively). Six independent prognostic factors were identified and used to build the scoring system, which performed well with a concordance index (C-index) of 0.759 (95% CI: 0.715-0.802); the calibration plot showed good calibration. Conclusions: We have established and verified a simple scoring system for predicting prognosis, which can predict the survival of patients with operable breast cancer. This system can help clinicians implement targeted and individualized treatment strategies. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Lin, Zhang, Xie, Huang, Chen, Jiang, Guo and Lin.) |
| References: | J Inflamm Res. 2021 Aug 20;14:4019-4033. (PMID: 34447260) PLoS One. 2018 Jul 26;13(7):e0200936. (PMID: 30048474) Br J Cancer. 2013 Oct 29;109(9):2316-22. (PMID: 24084772) Ann Surg Oncol. 2020 Oct;27(10):4028-4034. (PMID: 32314154) Cancer Manag Res. 2022 Feb 25;14:775-820. (PMID: 35241935) Genes (Basel). 2019 Jun 17;10(6):. (PMID: 31212963) Br J Cancer. 2020 Aug;123(3):403-409. (PMID: 32424148) Surg Today. 2022 Jan 11;:. (PMID: 35015151) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) Cancer Treat Rev. 2022 Mar;104:102339. (PMID: 35074727) Transl Oncol. 2022 Jan 6;17:101338. (PMID: 34999541) J Immunol Res. 2014;2014:149185. (PMID: 24901008) J Clin Oncol. 2013 Nov 1;31(31):3997-4013. (PMID: 24101045) Cancer Res. 2011 Apr 1;71(7):2411-6. (PMID: 21427354) Cancer Med. 2019 Aug;8(9):4135-4148. (PMID: 31197958) Eur J Cancer. 2021 Jun;150:155-167. (PMID: 33901794) CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204) Oncogene. 2017 Jan 26;36(4):482-490. (PMID: 27375023) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902) J Cancer Res Clin Oncol. 2022 Jan 31;:. (PMID: 35098389) J Clin Oncol. 2018 Jul 10;36(20):2105-2122. (PMID: 29846122) Ann Hepatol. 2021 May-Jun;22:100249. (PMID: 32896610) Clin Cancer Res. 2014 Dec 1;20(23):6212-22. (PMID: 25271081) Br J Cancer. 2014 May 13;110(10):2524-30. (PMID: 24675383) Breast Cancer. 2020 Jan;27(1):54-61. (PMID: 31280452) Front Oncol. 2020 Apr 21;10:580. (PMID: 32373539) J Natl Compr Canc Netw. 2006 Nov;4(10):971-9. (PMID: 17112447) Trends Cancer. 2017 Nov;3(11):753-760. (PMID: 29120751) Sci Rep. 2021 Jul 19;11(1):14662. (PMID: 34282214) Breast. 2019 Apr;44:33-38. (PMID: 30611095) Cancers (Basel). 2021 Apr 19;13(8):. (PMID: 33921727) Biometrics. 2008 Dec;64(4):1263-9. (PMID: 18325074) Ann Surg. 2021 Mar 03;:. (PMID: 33914478) J Am Coll Cardiol. 2020 Apr 14;75(14):1659-1672. (PMID: 32273031) Biomark Med. 2021 Oct;15(14):1289-1298. (PMID: 34486882) J Coll Physicians Surg Pak. 2022 Jan;32(1):86-91. (PMID: 34983154) Int J Biol Sci. 2017 Nov 1;13(11):1387-1397. (PMID: 29209143) Nat Commun. 2017 Aug 21;8(1):310. (PMID: 28827520) Lancet. 2021 May 8;397(10286):1750-1769. (PMID: 33812473) Clin Breast Cancer. 2020 Aug;20(4):e403-e409. (PMID: 32201163) Cancer Manag Res. 2020 Jan 21;12:475-484. (PMID: 32021460) Cancers (Basel). 2020 Dec 02;12(12):. (PMID: 33276569) Gastroenterology. 2016 Jun;150(7):1646-1658.e17. (PMID: 26924089) Immunity. 2019 Jul 16;51(1):27-41. (PMID: 31315034) Clin Cancer Res. 2013 Jun 1;19(11):2810-6. (PMID: 23549874) Breast Cancer Res. 2017 Jan 5;19(1):2. (PMID: 28057046) Annu Rev Immunol. 2004;22:329-60. (PMID: 15032581) Braz J Med Biol Res. 2021 Aug 13;54(10):e11409. (PMID: 34406210) World J Gastroenterol. 2014 Aug 14;20(30):10279-87. (PMID: 25132744) Onco Targets Ther. 2016 Jul 27;9:4653-60. (PMID: 27536129) Biomed Res Int. 2020 Dec 18;2020:7961568. (PMID: 33381583) Cancer Cell Int. 2020 Jun 09;20:224. (PMID: 32528232) Cell. 2010 Mar 19;140(6):883-99. (PMID: 20303878) J Clin Med. 2019 May 31;8(6):. (PMID: 31159309) BMC Med. 2020 Nov 20;18(1):360. (PMID: 33213430) Breast J. 2019 Sep;25(5):838-847. (PMID: 31192530) Cancer Med. 2020 Sep;9(18):6679-6693. (PMID: 33624450) PLoS One. 2017 May 10;12(5):e0177137. (PMID: 28489884) |
| فهرسة مساهمة: | Keywords: PIV; breast cancer; index; nomogram; prognosis |
| تواريخ الأحداث: | Date Created: 20220502 Latest Revision: 20220716 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9043599 |
| DOI: | 10.3389/fonc.2022.830138 |
| PMID: | 35494034 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2022.830138 |